Nebenwirkungen · Vectibix
Vectibix 20 mg/mL concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 10
HOS-117418 · Präparat HOS-094601
Across all clinical trials, skin reactions occurred in approximately 94% of patients receiving Vectibix as monotherapy or in combination with chemotherapy (n = 2 224). These reactions consisted predominantly of rash and dermatitis acneiform and were mostly mild to moderate in severity. Severe (grade 3) skin reactions were reported in 23% and life-threatening (grade 4) skin reactions in < 1% of patients. Life-threatening and fatal infectious complications including necrotising fasciitis and sepsis have been observed in patients treated with Vectibix (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-07T10:43:00Z · SHA-256 623c963b5fb57ad899208d5b3acaf4f91d25565ad9b26d6ae5a16bcb53a34569 · Passage 792ec9653106bf9d441b1823da1fb6d9d0538f91d228847e0a3429dbeb3dcdf2 · Zeichen 11156–11729 im Abschnitt